Brain NAD in Alzheimer's Disease

Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07127510

Acronym

ALZNAD

Enrollment

Registered

2025-08-17

Start date

2026-03-18

Completion date

2027-06-01

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease (AD)

Keywords

NAD, Alzheimer Disease (AD)

Brief summary

The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

65 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory. * Age 65 to 80 included. * People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.

Exclusion criteria

* Under the age of 65 or over the age of 80. * Advanced dementia such that the person would require sedation for undergoing an MRI scan. * Receiving anti-amyloid intravenous treatments Leqembi or Kinsula. * Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part). * Having a history of seizures. * Working at night. * Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer). * People with no AD: MoCA test result lower than 26.

Design outcomes

Primary

Measure	Time frame	Description
Brain NAD	At enrollment and 8 months after enrollment	NAD levels measured by 1H-MRS

Countries

United States

Contacts

CONTACTFAU Clinical Research Unit Central Contact

CRUDOR@health.fau.edu561-235-4467

PRINCIPAL_INVESTIGATORCorinne Lasmezas, PhD

Florida Atlantic University

Outcome results